Developer docs
API playgroundTry for free, no card

Search company profiles

Arecor

Full company profile

uuid0000532

Namestring
Arecor
Legal namestring
Arecor Therapeutics plc
Websiteurl
arecor.com
Company typeenum
Public
Founded yearint
2007
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersCambridge, United Kingdom
HQ citystring
Cambridge
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
drug formulation technology, biopharmaceutical development, insulin therapy, oral peptide delivery, technology licensing
Industry2 codes
PRIMARYHLAIALAH
Regulatory Strategy & IND/NDA/BLA Submissions Support
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAHAIAC
Pen Injectors (Insulin/GLP-1/Other Pens)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Drug Delivery Devices (Injectors, Pumps, Inhalers)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Services-Commercial Physical & Biological Research8731
Product category
Biopharmaceutical Formulation Technology
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model4 records
1Technology Licensing
TypeLicensing Royalties
Description

Partners pay technology development fees and upon completion have the option to enter into license agreements for rights to access IP and further develop and commercialise novel formulations. Licenses typically involve milestone and royalty payments.

arecor.com
2Royalty Rights Monetization
TypeLicensing Royalties
Description

Sale of global royalty rights to AT220 and all potential milestone and technology access fees related to AT292 to Ligand Pharmaceuticals for $11 million in September 2025. Ongoing milestone payments from Ligand.

globenewswire.com
3Co-development Agreements
TypeLicensing Royalties
Description

Revenue generating from co-development partnerships such as agreement with Sequel Med Tech for AT278 development. Partners share development costs and provide upfront payments.

arecor.com
4Existing License Revenue
TypeLicensing Royalties
Description

Revenue from existing partnerships including Sanofi programme SAR447437 (AT292), biosimilar product AT220 under worldwide licensing agreement, and AT351 under exclusive milestone and royalty-bearing licensing agreement.

arecor.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Arecor is a clinical-stage biopharmaceutical company that develops superior therapeutics for diabetes, obesity and other cardiometabolic diseases using its proprietary Arestat® drug formulation technology platform. It licenses Arestat to leading pharmaceutical and medtech partners in exchange for development fees, milestone payments and royalties, while also advancing its own proprietary pipeline including AT278 (ultra-concentrated ultra-rapid-acting insulin for AID systems) and an oral GLP-1 receptor agonist programme.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • AT278 shows best-in-class profile compared to best gold-standard insulins currently available
+3 more records
Product overview1 text field

Arecor is a clinical-stage biotech company developing superior therapeutics for diabetes, obesity, and other cardiometabolic diseases using its proprietary Arestat technology platform. The company's portfolio includes proprietary products (AT278, an ultra-concentrated ultra-rapid-acting insulin for AID systems, and an oral GLP-1 receptor agonist programme) alongside partnered products (AT220 biosimilar, AT292/SAR447537 licensed to Sanofi, and AT351). Arecor operates as a platform company, licensing its Arestat technology to pharmaceutical partners while advancing its own pipeline.

Product and service6 records
1AT278
CategoryProprietary Insulin Therapy
Description

Best-in-class, ultra-concentrated (500U/mL), ultra-rapid-acting insulin designed to transform Automated Insulin Delivery (AID) systems. The only insulin suitable for AID pump use in high insulin users, enabling next-generation miniaturised, longer-wear pumps for Type 1 and Type 2 diabetes patients. Co-developed with Sequel Med Tech for use in the twiist AID system.

2AT220
CategoryLicensed Biosimilar Product
Description

Arestat-enhanced biosimilar product under a worldwide licensing agreement, generating licensing and royalty revenue for Arecor; global royalty rights were subsequently sold to Ligand Pharmaceuticals for $11 million in September 2025.

3AT292 (SAR447537)
CategoryLicensed Biologic Programme
Description

Sanofi's programme (formerly INBRX-101) incorporating Arestat® technology under a revenue-generating licence. Generates milestone and royalty payments for Arecor from Sanofi's development and commercialisation.

4AT351
CategoryLicensed Specialty Product
Description

Arestat-enhanced product under an exclusive milestone and royalty-bearing licensing agreement with a subsidiary of one of the world's largest independent chemicals marketing companies, providing an additional technology-licensing revenue stream.

5Oral GLP-1 Receptor Agonist (Semaglutide) Programme
CategoryProprietary Oral Peptide Programme
Description

Novel oral delivery platform for peptides, initially targeting an oral GLP-1 receptor agonist (semaglutide) with significantly improved bioavailability versus current marketed products (Rybelsus achieves less than 1% bioavailability). Addresses the multi-billion dollar obesity and cardiometabolic disease markets.

6Arestat® Technology Platform
CategoryProprietary Drug Formulation Platform
Description

Proprietary formulation and drug delivery technology platform licensed to pharmaceutical and biotech partners to develop products with enhanced properties including improved stability, extended shelf-life, cold-chain elimination, high-concentration low-viscosity subcutaneous formulations, ready-to-use and ready-to-administer IV formats, lyophilised-to-liquid switches, and controlled pharmacokinetic / pharmacodynamic profiles.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2026-01-01
Description

Industry partner in University of Virginia $4.7M AI-powered diabetes management project. Tandem provides in-kind contributions totaling $800,000 alongside $3.9M grant from Breakthrough T1D and Helmsley Charitable Trust. Collaboration focuses on next-generation fully closed-loop insulin delivery systems combining adaptive ML algorithms with ultra-rapid-acting insulin.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-09-01
Description

Co-development agreement with US insulin pump developer for AT278, an ultra-concentrated insulin, to undertake preparatory work for Phase 2 clinical trial for combined AT278/Insulin Pump programme. AT278 will be used in Sequel's twiist AID system which precisely measures each dose of insulin.

Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2025-01-01
Description

Collaboration partnership announced in 2025 focused on undisclosed therapeutic development. Demonstrates growing partnership pipeline and value of Arecor's technology platform.

Strategic tierStrategicTypeTechnology or Integration
Description

Sanofi's programme SAR447537 (formerly INBRX-101, now AT292) incorporates Arestat technology under a revenue-generating license. Arecor receives milestone and royalty payments from this partnership.

Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

Acquired by Arecor Therapeutics in August 2022 (contingent upon successful capital offering). Tetris was Xeris' commercialization partner for Ogluo glucagon rescue pen in UK, EEA, and Switzerland. Business ceased operations in 2025.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Halozyme operates the ENHANZE drug delivery platform, licensing it to major pharmaceutical companies for subcutaneous formulation of biologics — closely mirroring Arecor's Arestat platform licensing model with Big Pharma partners.

TypeDirect peer
Description

Adocia develops innovative formulations of insulin and other peptides for diabetes, including ultra-rapid-acting insulin analogues using its BioChaperone platform — directly competitive with Arecor's AT278 in the ultra-rapid insulin space.

TypeDirect peer
Description

MannKind develops Technosphere drug delivery technology and commercialized Afrezza inhaled insulin — a small-cap diabetes specialist with a proprietary delivery platform addressing similar unmet needs to Arecor's Arestat platform.

TypeDirect peer
Description

Xeris develops ready-to-use, room-temperature-stable injectable formulations (including Ogluo glucagon, which Arecor previously commercialized through Tetris) — a direct peer in formulation technology and diabetes/endocrine therapies.

TypeDirect peer
Description

Zealand Pharma is a clinical-stage peptide therapeutics company with platform technology for modified peptides, including programmes in diabetes/obesity — comparable to Arecor's peptide-focused, platform-driven development model.

TypeEmerging player
Description

Crinetics is an emerging clinical-stage biotech developing peptide therapeutics for endocrine diseases — a peer in modality and therapeutic focus, though focused on rare endocrine conditions rather than diabetes/obesity.

TypeBroad incumbent
Description

Eli Lilly is a global pharmaceutical incumbent with dominant diabetes (Humalog, Lyumjev) and obesity (Mounjaro/Zepbound) franchises — sets the competitive bar in Arecor's target therapeutic areas and has deep formulation and pump-partner relationships.

TypeBroad incumbent
Description

Novo Nordisk is the global leader in diabetes care and GLP-1 receptor agonists (Rybelsus is the established oral semaglutide) — represents both the dominant competitor and the standard Arecor must surpass with its oral peptide platform.

TypeBroad incumbent
Description

Sanofi is both Arecor's licensing partner (AT292/SAR447537) and a broad incumbent in diabetes (Lantus, Toujeo) and cardiometabolic disease — comparable as a potential acquirer and as a benchmark for the kind of large-pharma relationships Arecor is building.

TypeEmerging player
Description

Tandem is a leading US insulin pump and AID system developer and an industry partner with Arecor in the University of Virginia AI-powered diabetes management project — a peer and ecosystem partner in the AID system market that AT278 is designed to serve.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds12 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors12 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Arecor

Biopharmaceutical Formulation Technologyarecor.com

Arecor firmographics

Firmographics
Name
Arecor
Legal name
Arecor Therapeutics plc
Website
https://arecor.com
Company type
Public
Founded year
2007
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

Arecor industry classification

Industry
Product category
Biopharmaceutical Formulation Technology
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAIALAH
Regulatory Strategy & IND/NDA/BLA Submissions Support
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAHAIAC
Pen Injectors (Insulin/GLP-1/Other Pens)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Drug Delivery Devices (Injectors, Pumps, Inhalers)

Keywords

  • Drug formulation technology
  • Biopharmaceutical development
  • Insulin therapy
  • Oral peptide delivery
  • Technology licensing

Where Arecor is headquartered

Location

Headquarters

HQ city
Cambridge
HQ country
United Kingdom
HQ region
Europe

Offices1 record

Markets served

Arecor business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

  1. Technology Licensing: Partners pay technology development fees and upon completion have the option to enter into license agreements for rights to access IP and further develop and commercialise novel formulations. Licenses typically involve milestone and royalty payments.
  2. Royalty Rights Monetization: Sale of global royalty rights to AT220 and all potential milestone and technology access fees related to AT292 to Ligand Pharmaceuticals for $11 million in September 2025. Ongoing milestone payments from Ligand.
  3. Co-development Agreements: Revenue generating from co-development partnerships such as agreement with Sequel Med Tech for AT278 development. Partners share development costs and provide upfront payments.
  4. Existing License Revenue: Revenue from existing partnerships including Sanofi programme SAR447437 (AT292), biosimilar product AT220 under worldwide licensing agreement, and AT351 under exclusive milestone and royalty-bearing licensing agreement.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels6 records

Arecor product offering

Product offering

Core offering

Arecor is a clinical-stage biopharmaceutical company that develops superior therapeutics for diabetes, obesity and other cardiometabolic diseases using its proprietary Arestat® drug formulation technology platform. It licenses Arestat to leading pharmaceutical and medtech partners in exchange for development fees, milestone payments and royalties, while also advancing its own proprietary pipeline including AT278 (ultra-concentrated ultra-rapid-acting insulin for AID systems) and an oral GLP-1 receptor agonist programme.

Product overview

Arecor is a clinical-stage biotech company developing superior therapeutics for diabetes, obesity, and other cardiometabolic diseases using its proprietary Arestat technology platform. The company's portfolio includes proprietary products (AT278, an ultra-concentrated ultra-rapid-acting insulin for AID systems, and an oral GLP-1 receptor agonist programme) alongside partnered products (AT220 biosimilar, AT292/SAR447537 licensed to Sanofi, and AT351). Arecor operates as a platform company, licensing its Arestat technology to pharmaceutical partners while advancing its own pipeline.

Differentiator

Problem solved

Functional benefit

Products and services

  • AT278 Best-in-class, ultra-concentrated (500U/mL), ultra-rapid-acting insulin designed to transform Automated Insulin Delivery (AID) systems. The only insulin suitable for AID pump use in high insulin users, enabling next-generation miniaturised, longer-wear pumps for Type 1 and Type 2 diabetes patients. Co-developed with Sequel Med Tech for use in the twiist AID system.
  • AT220 Arestat-enhanced biosimilar product under a worldwide licensing agreement, generating licensing and royalty revenue for Arecor; global royalty rights were subsequently sold to Ligand Pharmaceuticals for $11 million in September 2025.
  • AT292 (SAR447537) Sanofi's programme (formerly INBRX-101) incorporating Arestat® technology under a revenue-generating licence. Generates milestone and royalty payments for Arecor from Sanofi's development and commercialisation.
  • AT351 Arestat-enhanced product under an exclusive milestone and royalty-bearing licensing agreement with a subsidiary of one of the world's largest independent chemicals marketing companies, providing an additional technology-licensing revenue stream.
  • Oral GLP-1 Receptor Agonist (Semaglutide) Programme Novel oral delivery platform for peptides, initially targeting an oral GLP-1 receptor agonist (semaglutide) with significantly improved bioavailability versus current marketed products (Rybelsus achieves less than 1% bioavailability). Addresses the multi-billion dollar obesity and cardiometabolic disease markets.
  • Arestat® Technology Platform Proprietary formulation and drug delivery technology platform licensed to pharmaceutical and biotech partners to develop products with enhanced properties including improved stability, extended shelf-life, cold-chain elimination, high-concentration low-viscosity subcutaneous formulations, ready-to-use and ready-to-administer IV formats, lyophilised-to-liquid switches, and controlled pharmacokinetic / pharmacodynamic profiles.

Quantifiable outcome

  • AT278 shows best-in-class profile compared to best gold-standard insulins currently available
  • +3 more outcomes

Companies that use Arecor

Customer profile

Named customers5 records

Segments4 records

Ideal customer profiles2 records

Arecor technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Arecor partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered strategic, core and minor.

  • Tandem Diabetes CarestrategicStrategic or Co-development Partner · 1 January 2026Industry partner in University of Virginia $4.7M AI-powered diabetes management project. Tandem provides in-kind contributions totaling $800,000 alongside $3.9M grant from Breakthrough T1D and Helmsley Charitable Trust. Collaboration focuses on next-generation fully closed-loop insulin delivery systems combining adaptive ML algorithms with ultra-rapid-acting insulin.
  • Sequel Med TechcoreStrategic or Co-development Partner · 1 September 2025Co-development agreement with US insulin pump developer for AT278, an ultra-concentrated insulin, to undertake preparatory work for Phase 2 clinical trial for combined AT278/Insulin Pump programme. AT278 will be used in Sequel's twiist AID system which precisely measures each dose of insulin.
  • Skye BioSciencestrategicStrategic or Co-development Partner · 1 January 2025Collaboration partnership announced in 2025 focused on undisclosed therapeutic development. Demonstrates growing partnership pipeline and value of Arecor's technology platform.
  • SanofistrategicTechnology or IntegrationSanofi's programme SAR447537 (formerly INBRX-101, now AT292) incorporates Arestat technology under a revenue-generating license. Arecor receives milestone and royalty payments from this partnership.
  • Tetris Pharma LtdminorChannel Partner/ Reseller/ DistributorAcquired by Arecor Therapeutics in August 2022 (contingent upon successful capital offering). Tetris was Xeris' commercialization partner for Ogluo glucagon rescue pen in UK, EEA, and Switzerland. Business ceased operations in 2025.

Scale indicators8 records

Recent moves7 records

Expansion highlights5 records

Arecor competitors and assessment

Company assessment

Direct peers

  • Halozyme Therapeutics: Halozyme operates the ENHANZE drug delivery platform, licensing it to major pharmaceutical companies for subcutaneous formulation of biologics — closely mirroring Arecor's Arestat platform licensing model with Big Pharma partners.
  • Adocia: Adocia develops innovative formulations of insulin and other peptides for diabetes, including ultra-rapid-acting insulin analogues using its BioChaperone platform — directly competitive with Arecor's AT278 in the ultra-rapid insulin space.
  • MannKind Corporation: MannKind develops Technosphere drug delivery technology and commercialized Afrezza inhaled insulin — a small-cap diabetes specialist with a proprietary delivery platform addressing similar unmet needs to Arecor's Arestat platform.
  • Xeris Biopharma: Xeris develops ready-to-use, room-temperature-stable injectable formulations (including Ogluo glucagon, which Arecor previously commercialized through Tetris) — a direct peer in formulation technology and diabetes/endocrine therapies.
  • Zealand Pharma: Zealand Pharma is a clinical-stage peptide therapeutics company with platform technology for modified peptides, including programmes in diabetes/obesity — comparable to Arecor's peptide-focused, platform-driven development model.

Emerging players

  • Crinetics Pharmaceuticals: Crinetics is an emerging clinical-stage biotech developing peptide therapeutics for endocrine diseases — a peer in modality and therapeutic focus, though focused on rare endocrine conditions rather than diabetes/obesity.
  • Tandem Diabetes Care: Tandem is a leading US insulin pump and AID system developer and an industry partner with Arecor in the University of Virginia AI-powered diabetes management project — a peer and ecosystem partner in the AID system market that AT278 is designed to serve.

Broad incumbents

  • Eli Lilly: Eli Lilly is a global pharmaceutical incumbent with dominant diabetes (Humalog, Lyumjev) and obesity (Mounjaro/Zepbound) franchises — sets the competitive bar in Arecor's target therapeutic areas and has deep formulation and pump-partner relationships.
  • Novo Nordisk: Novo Nordisk is the global leader in diabetes care and GLP-1 receptor agonists (Rybelsus is the established oral semaglutide) — represents both the dominant competitor and the standard Arecor must surpass with its oral peptide platform.
  • Sanofi: Sanofi is both Arecor's licensing partner (AT292/SAR447537) and a broad incumbent in diabetes (Lantus, Toujeo) and cardiometabolic disease — comparable as a potential acquirer and as a benchmark for the kind of large-pharma relationships Arecor is building.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

Arecor social profiles

Digital presence

Arecor financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Arecor leadership team

Management profile

Number of profiles

Profiles8 records

Arecor subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

Arecor funding detail

Funding detail

Funding overview

Funding rounds12 records

Investors12 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Arecor M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Arecor

What does Arecor do?

Arecor is a clinical-stage biopharmaceutical company that develops superior therapeutics for diabetes, obesity and other cardiometabolic diseases using its proprietary Arestat® drug formulation technology platform. It licenses Arestat to leading pharmaceutical and medtech partners in exchange for development fees, milestone payments and royalties, while also advancing its own proprietary pipeline including AT278 (ultra-concentrated ultra-rapid-acting insulin for AID systems) and an oral GLP-1 receptor agonist programme.

Is Arecor a public or private company?

Arecor is a public company. It is classified as public and is currently operating.

When was Arecor founded?

Arecor was founded in 2007. It employs 11 to 50 people.

Where is Arecor based?

Arecor is headquartered in Cambridge, United Kingdom, in the Europe region.

How does Arecor make money?

Four revenue lines are on record. Technology Licensing is the primary driver. The others are royalty Rights Monetization, co-development Agreements and existing License Revenue.

Who are Arecor's main competitors?

Direct peers on record are Halozyme Therapeutics, Adocia, MannKind Corporation, Xeris Biopharma and Zealand Pharma. Emerging players are Crinetics Pharmaceuticals and Tandem Diabetes Care. Broad incumbents are Eli Lilly, Novo Nordisk and Sanofi.

Does Arecor have an API?

No public API is recorded for Arecor.

What industry is Arecor in?

Arecor's product category is Biopharmaceutical Formulation Technology. Its primary akta.pro industry code is HLAIALAH, Regulatory Strategy & IND/NDA/BLA Submissions Support, with a secondary code of HLAHAIAC, Pen Injectors (Insulin/GLP-1/Other Pens). Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
InvestegatePatents for concentrated ultra-rapid insulinsArecor Therapeutics secured new patents for its AT278 concentrated ultra-rapid insulin in the EPO, USPTO, and India, extending terms to at least 2039. The patents cover use in automated insulin delivery systems, targeting about four million U.S. patients needing intensive insulin therapy. Arecor identifies a $3 billion U.S. revenue opportunity for its insulins.InvestegateRetail Offer to raise up to £130,000Arecor Therapeutics announced a retail offer of up to 191,176 new ordinary shares at 68 pence each, open to UK shareholders via BookBuild. The offer is conditional on a separate placing of 7,352,941 shares raising about £5.0 million, with second admission expected on 9 October 2026.InvestegateClose of Accelerated Bookbuild to New OrdersArecor Therapeutics announced the close of its accelerated bookbuild to new orders on 30 September 2026. The company will issue a further update on the placing results and completion timetable. The announcement contains inside information and is for informational purposes only.Simply Wall StArecor Therapeutics Among 3 UK Penny Stocks To ConsiderA Simply Wall St article profiles three UK penny stocks, citing Arecor Therapeutics, Goldplat PLC and Intercede Group plc. Arecor, a clinical-stage biotech with a £24.92 million market cap, reported £1.71 million revenue and a one-off £5 million gain. Goldplat, a mining services firm, posted -35.1% earnings growth, while Intercede, a cybersecurity company, remains debt-free.ProactiveinvestorsArecor's ultra-concentrated insulin holds ultra-rapid profile in peer-reviewed study - UPDATEArecor Therapeutics PLC published full peer-reviewed clinical results for its experimental ultra-concentrated insulin, AT278, demonstrating that it maintains an ultra-rapid onset of action in heavier patients, addressing a key limitation of existing high-strength formulations. The trial data showed AT278 was absorbed significantly faster than comparators with no safety concerns, leading to a 7% rise in the company's share price. Arecor positions this formulation to fill a gap for patients requiring large daily doses and to enable smaller automated insulin delivery systems.Investing.comArecor publishes AT278 study in peer-reviewed journal By Investing.comArecor Therapeutics announced the publication of clinical data from its AT278-104 study in the peer-reviewed journal Diabetes, Obesity & Metabolism. The study demonstrated that the investigational ultra-concentrated insulin aspart formulation exhibits faster absorption and a greater glucose-lowering effect within the first hour compared to standard concentration insulins.Markets DailyArecor Therapeutics (LON:AREC) Shares Down 3.1% – What’s Next?Arecor Therapeutics plc shares declined 3.1% during mid-day trading on Friday, dropping to GBX 61.50 from a previous close of GBX 63.50, with trading volume surging 201% above the daily average. The clinical-stage biotech company, valued at £23.22 million, is developing AT278, an ultra-concentrated ultra-rapid-acting insulin, and has a strategic partnership with Sequel Med Tech to co-develop the product with their twiist automated insulin delivery system.BioSpaceThe next era of diabetes managementThis article serves as a promotional description for an episode of the 'Denatured' podcast, featuring Dr. Sarah Howell, CEO of Arecor Therapeutics, and Dr. Wendy S. Lane from the Mountain Diabetes and Endocrine Center. The discussion focuses on how connected and personalized diabetes technologies are reducing the daily burden of managing the condition. It highlights the integration of technology in healthcare to improve patient quality of life.openPR.comGlobal Drivers Overview: The Rapid Evolution of the Implantable Drug Delivery Devices MarketThe Business Research Company published a market report projecting the implantable drug delivery devices market to reach $33.39 billion by 2030, growing at a compound annual growth rate of 8.7%, driven by technological advancements, personalized drug delivery solutions, and increasing regulatory approvals. In May 2024, UK-based biopharmaceutical firm Arecor entered a collaboration with Medtronic to develop a highly concentrated, stable liquid formulation of Arestat-enabled insulin specifically for implantable delivery systems. The report identifies key market trends including adoption of controlled-release implant systems, bio-absorbable materials, site-specific drug delivery, and miniaturization of devices.